Anxiety Disorders

Anxiety disorders are the most common mental health conditions in the United States, affecting approximately 40 million adults — nearly 19% of the population. These include generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, and specific phobias.

While many patients respond well to first-line treatments such as SSRIs, SNRIs, and cognitive-behavioral therapy (CBT), a significant subset — estimated at 30–40% of anxiety disorder patients — do not achieve adequate relief. For these individuals, ketamine therapy is emerging as a promising alternative with rapid-onset anxiolytic effects.

The burden of treatment-resistant anxiety extends beyond mental distress: it is associated with increased cardiovascular risk, chronic pain, substance use, and significant impairment in occupational and social functioning.

Ketamine's anxiolytic effects appear to work through several interconnected mechanisms:

• Glutamate modulation: By blocking NMDA receptors and enhancing AMPA receptor signaling, ketamine rapidly normalizes glutamate transmission in anxiety-related brain circuits, particularly the amygdala and prefrontal cortex.
• Synaptic restoration: Chronic anxiety causes dendritic atrophy and loss of synaptic connections in the prefrontal cortex, reducing the brain's capacity for emotional regulation. Ketamine rapidly promotes synaptogenesis, helping restore top-down control over anxiety responses.
• GABAergic effects: Ketamine may indirectly enhance GABAergic inhibitory function, promoting a calming effect on overactive fear circuits.
• Neuroinflammation reduction: Growing evidence links anxiety disorders to elevated neuroinflammation. Ketamine's anti-inflammatory properties may contribute to its anxiolytic effects.
• Rapid cortisol normalization: Some research suggests ketamine helps normalize the dysregulated stress response system in anxiety disorders.

Treatment protocols for anxiety disorders with ketamine include:

• Induction series: Typically 6 IV infusions over 2–3 weeks at 0.5 mg/kg over 40 minutes. Some clinicians use slightly lower doses for anxiety-predominant presentations to minimize dissociative effects.
• Dose titration: Clinicians may start at a lower dose (0.25–0.35 mg/kg) and titrate upward based on response and tolerability, as some anxiety patients are more sensitive to dissociative effects.
• Maintenance: Responders continue with maintenance infusions every 2–6 weeks. The frequency is adjusted based on the duration of anxiolytic effects between sessions.
• Combination approach: Ketamine is most effective when combined with ongoing cognitive-behavioral therapy (CBT), acceptance and commitment therapy (ACT), or other evidence-based psychotherapies.

Key safety considerations for anxiety patients:

• Paradoxical anxiety: A small percentage of patients may experience increased anxiety during the infusion, particularly during onset. This is typically transient and manageable with supportive care and environmental adjustments.
• Dissociation sensitivity: Patients with anxiety may be more sensitive to dissociative effects. Starting at a lower dose and titrating slowly can help mitigate this.
• Panic disorder considerations: Patients with panic disorder should be informed about the physical sensations that may occur during infusion so they can differentiate them from panic symptoms.
• Benzodiazepine interactions: Concurrent benzodiazepine use may reduce ketamine's efficacy. Clinicians should discuss tapering strategies when appropriate.